Health
Personalized mRNA Vaccine Passes Phase 3 Milestone for Melanoma Treatment
Moderna and Merck announced on August 19, 2026, that their personalized mRNA cancer vaccine, intismeran autogene, has successfully met its primary endpoints in a 1,137-patient Phase 3 clinical trial. The therapy significantly reduces the risk of recurrence and distant metastasis in patients with completely resected stage IIB-IV melanoma.